



Supplementary Figures and Supplementary Figure Legends



Supplementary Fig 1. Correlation of anti-spike and anti-RBD antibodies in the saliva and serum after two-doses of mRNA vaccine


(A-D) N=128 Subjects were sampled 2-4 weeks after their second dose of either BNT162b2 or mRNA-1273. The indicated antibody isotypes (IgA and IgG) were analyzed in serum and saliva via an ELISA-based method. A Spearman test was used to calculate the correlation coefficient for each plot. We observed significant positive correlations for anti-RBD IgG (B), anti-Spike IgA (C) and anti-RBD IgA (D) in saliva and serum. We did not observe a significant correlation for anti-Spike IgG antibodies (A); however, this was due to oversaturation of signal in the serum. We therefore repeated the analysis for anti-Spike IgG using a lower concentration on a subset (n=39) of samples (E) using the 3rd point on the titration curve (F) and observed a significant positive correlation between serum and saliva titers. ns= not significant, **=p<0.01, ***=p<0.001 and ****=p<0.0001.



Supplementary Fig 2. Correlation of anti-spike and anti-RBD antibodies in the saliva and serum after a single dose of mRNA vaccine in the MSB-1 cohort.


(A-D) N=27 MSB-1 participants were sampled 2-4 weeks after 1 dose with BNT162b2. The indicated antibody isotypes (IgA and IgG) were analyzed in serum and saliva via an ELISA-based method. Spearman test was used to calculate the correlation coefficient for each plot. ns= not significant, *= $p<0.05$ and **= $p<0.001$.

**Effect of incubating recombinant secretory protein
with α -secretory antibody prior to use in secretory component ELISA**




Supplementary Figure 3. Secretory component detected in antigen-specific antibodies from COVID-19 patient saliva

Validation of secretory component assay was confirmed by outcompeting signal with recombinant secretory component. We observed that incubation of COVID-19 positive samples with recombinant secretory component prior to incubation in the experimental plate brought signal down to negative control levels in a concentration-dependent manner. Pre-pandemic colostrum showed no evidence of anti-Spike/RBD associated secretory component signal, as expected. Mann-Whitney U test was used to calculate significance between groups, where ***=p<0.0001.




Supplementary Figure 4. Comparison of anti-Spike/RBD IgG levels in the serum in the LTCH, MSB-1 and MSB-2 cohorts.

(A, B) Subjects who received 2 doses of mRNA vaccines (LTCH, MSB-1) or 1 dose of ChAdOx1-S followed by a second dose of either BNT162b2 or mRNA1273 were sampled 2-4 weeks post-dose 2. Anti-spike and anti-RBD antibody levels were analyzed in serum via an ELISA-based method. We observed that subjects who received 2 doses of mRNA vaccines with doses 1 and 2 21-28 days apart (LTCH, n=93) had significantly higher levels of serum titres compared to subjects who received 2 doses of mRNA vaccines but doses 1 and 2 were 3 months apart (MSB-1, n=27). However, when comparing mRNA/mRNA (MSB-1) to Ad/mRNA (MSB-2, n=36) when both groups received delayed second doses, the difference in serum antibody titres was not significant. Spearman test was used to calculate the correlation coefficient for each plot, where ***= $p<0.0001$.



Supplementary Figure 5. Correlation of anti-spike and anti-RBD antibodies in the saliva and serum after 2 vaccine doses

Participants from either MSB-1 or MSB-2 cohorts were sampled 2-4 weeks after 2 doses of BNT162b2 (MSB-1) or 1 dose of ChAdOx1-S and a second dose of either BNT162b2 or mRNA1273 (MSB-2). IgA and IgG were analyzed in serum and saliva, and a Spearman test was used to calculate correlation coefficients. ns= not significant, *= $p<0.05$ and **= $p<0.001$.



Supplementary Figure 6. Neutralizing antibodies detected in the saliva of vaccinated subjects

Saliva from MSB-1 (A,B,C) or MSB-2 (D,E) was assessed for the presence of neutralizing antibodies and results were expressed as a percentage of maximum infection, where a lower percentage indicates decreased infection of hACE-2 HEK293 cells by rVSV-eGFP-SARS-CoV-2-Spike. (A)- Longitudinal assessment of a subset of MSB-1 subjects (n=9). (B)- Neutralization potential at different dilutions of saliva from n=30 MSB-1 participants. (C)- Fluorescent reduction neutralization titre (FRNT) using a cut off of either 50% or 70% neutralization (FRNT50 and FRNT70, respectively) from n=30 MSB-1 participants. (D)- Neutralization potential at different dilutions of saliva from n=36 MSB-2 participants. (E)- Fluorescent reduction neutralization titre (FRNT) using a cut off of either 50% or 70% neutralization (FRNT50 and FRNT70, respectively) from n=36 MSB-2 participants. Mann-Whitney U test was used to calculate significance between groups, where ns=not significant.

SupplementaryTable 1. LTCH cohort (mRNA/mRNA)

Participant ID	Age	Sex	Vaccine type	Interval between dose 1 and dose 2 (weeks)
1	46-50	F	mRNA1273	4.0
2	61-65	F	mRNA1273	4.7
3	46-50	F	BNT162b2	5.9
4	41-45	F	mRNA1273	4.0
5	56-60	F	BNT162b2	3.0
6	41-45	F	mRNA1273	4.0
7	56-60	F	mRNA1273	4.0
8	41-45	F	BNT162b2	5.0
9	56-60	F	mRNA1273	4.0
10	46-50	F	mRNA1273	4.0
11	36-40	F	BNT162b2	5.0
12	51-55	M	BNT162b2	2.9
13	56-60	F	mRNA1273	2.9
14	46-50	F	BNT162b2	5.6
15	31-35	F	BNT162b2	5.3
16	51-55	F	BNT162b2	5.6
17	61-65	F	BNT162b2	47.7
18	51-55	F	BNT162b2	4.4
19	51-55	F	mRNA1273	4.0
20	61-65	F	BNT162b2	5.0
21	56-60	F	BNT162b2	5.0
22	26-30	F	BNT162b2	5.6
23	56-60	F	BNT162b2	5.6
24	46-50	F	BNT162b2	5.6
25	41-45	F	BNT162b2	5.6
26	36-40	F	BNT162b2	5.6
27	61-65	F	BNT162b2	5.6
28	51-55	F	BNT162b2	5.6
29	41-45	F	BNT162b2	5.6
30	51-55	M	BNT162b2	7.0
31	61-65	F	BNT162b2	5.6
32	46-50	F	BNT162b2	5.0
33	26-30	F	BNT162b2	5.6
34	31-35	M	BNT162b2	5.6
35	36-40	F	mRNA1273	4.0
36	31-35	F	BNT162b2	5.0
37	41-45	F	BNT162b2	5.6
38	26-30	F	BNT162b2	5.6
39	41-45	F	BNT162b2	5.0
40	61-65	F	BNT162b2	6.4
41	36-40	M	BNT162b2	5.6
42	31-35	F	mRNA1273	4.0
43	36-40	M	mRNA1273	4.0

44	51-55	F	mRNA1273	3.0
45	46-50	M	mRNA1273	4.0
46	26-3-	F	mRNA1273	4.0
47	56-60	F	mRNA1273	4.0
48	31-35	F	mRNA1273	5.0
49	56-60	M	mRNA1273	4.9
50	51-55	F	mRNA1273	5.0
51	41-45	F	mRNA1273	4.1
52	51-55	F	mRNA1273	2.9
53	36-40	F	BNT162b2	4.6
54	41-45	F	BNT162b2	4.1
55	61-65	F	BNT162b2	3.4
56	61-65	F	BNT162b2	4.6
57	20-25		BNT162b2	3.7
58	20-25	F	BNT162b2	4.9
59	31-35	F	BNT162b2	3.0
60	26-30	F	BNT162b2	4.4
61	31-35	F	BNT162b2	3.7
62	46-50	F	BNT162b2	4.9
63	36-40	M	BNT162b2	3.0
64	61-65	M	BNT162b2	4.6
65	46-50	F	BNT162b2	3.1
66	61-65	F	BNT162b2	5.0
67	26-30	F	BNT162b2	4.7
68	51-55	F	BNT162b2	4.4
69	46-50	F	BNT162b2	3.0
70	41-45	F	BNT162b2	3.9
71	51-55	F	BNT162b2	3.9
72	31-35	F	BNT162b2	8.4
73	46-50	F	BNT162b2	6.9
74	51-55	F	BNT162b2	3.0
75	20-25	F	BNT162b2	3.1
76	20-25		BNT162b2	3.7
77	51-55	F	BNT162b2	3.0
78	56-60	F	BNT162b2	4.7
79	20-25	F	BNT162b2	3.1
80	55-60	F	BNT162b2	5.1
81	36-40	M	BNT162b2	5.0
82	26-30	F	BNT162b2	5.0
83	56-60	F	BNT162b2	4.0
84	20-25	F	mRNA1273	4.0
85	20-25	F	BNT162b2	5.0
86	46-50	M	mRNA1273	3.4
87	41-45	F	BNT162b2	5.0
88	66-70	F	BNT162b2	5.0
89	36-40	M	mRNA1273	3.0
90	31-35	F	BNT162b2	3.0
91	31-35	F	mRNA1273	3.4
92	20-25	F	BNT162b2	3.0
93	26-30	F	mRNA1273	3.0
94	20-25	F	BNT162b2	3.0
95	41-45	F	BNT162b2	3.0
96	61-65	F	mRNA1273	3.0

97	56-60	F	mRNA1273	4.0
98	41-45	F	BNT162b2	49.1
99	26-30	F	BNT162b2	49.1
100	56-60	F	mRNA1273	3.0
101	26-30	F	mRNA1273	4.0
102	36-40	F	BNT162b2	3.0
103	61-65	F	mRNA1273	3.6
104	36-40	F	BNT162b2	5.0
105	26-30	F	mRNA1273	3.4
106	20-25	F	mRNA1273	4.0
107	71-75	F	mRNA1273	
Summary	Median=46	%M=11 %F=89	%mRNA1273=32 %BNT162b2=68	Median=4.4

Supplementary Table 2a. COVID-19 negative controls

Participant ID	Age	Sex	Collection period	Used in Fig 1, Supp Fig 3 or as pooled negative
108	26-30	M	COVID era	Supp Fig 3
109	20-25	F	COVID era	Supp Fig 3
110	61-65	M	COVID era	Supp Fig 3
111	36-40	M	COVID era	Supp Fig 3
112	56-6-	F	COVID era	Supp Fig 3
113	41-45	M	COVID era	Supp Fig 3
114	46-50	F	COVID era	Supp Fig 3
115	26-30	M	COVID era	Supp Fig 3
116	31-35	F	COVID era	Supp Fig 3
117	31-35	M	COVID era	Supp Fig 3
118	36-40	F	COVID era	Supp Fig 3
119	36-40	M	COVID era	Supp Fig 3
120	31-35	M	COVID era	Supp Fig 3
121	36-40	M	COVID era	Supp Fig 3
122	66-70	F	COVID era	Supp Fig 3
123	66-70	M	COVID era	Supp Fig 3
124	91-95	F	COVID era	Supp Fig 3
125	36-40	M	COVID era	Supp Fig 3
126	71-75	F	COVID era	Supp Fig 3
127	66-70	M	COVID era	Supp Fig 3
128	36-40	F	COVID era	Supp Fig 3
129	41-45	M	COVID era	Supp Fig 3
130	41-45	M	COVID era	Supp Fig 3
131	51-55	M	COVID era	Supp Fig 3
132	61-65	M	COVID era	Supp Fig 3
133	56-60	F	COVID era	Supp Fig 3
134	61-65	M	COVID era	Supp Fig 3
135	71-75	M	COVID era	Supp Fig 3
136	81-85	F	COVID era	Supp Fig 3
137	51-55	M	COVID era	Supp Fig 3
138	71-75	M	COVID era	Supp Fig 3
139	61-65	F	COVID era	Supp Fig 3
140	61-65	M	COVID era	Supp Fig 3
141	81-85	F	COVID era	Supp Fig 3
142	46-50	M	COVID era	Supp Fig 3
143	66-70	F	COVID era	Supp Fig 3
144	20-25	F	COVID era	Supp Fig 3
145	66-70	F	COVID era	Supp Fig 3
146	26-30	M	COVID era	Supp Fig 3
147	61-65	F	COVID era	Supp Fig 3
148	61-65	M	COVID era	Supp Fig 3
149	41-45	M	COVID era	Supp Fig 3
150	61-65	M	COVID era	Supp Fig 3
151	86-90	M	COVID era	Supp Fig 3
152	81-85	F	COVID era	Supp Fig 3
153	81-85	M	COVID era	Supp Fig 3
154	76-80	M	COVID era	Supp Fig 3
155	56-60	M	COVID era	Supp Fig 3
156	56-60	M	COVID era	Supp Fig 3
Summary	Median age=58	%M=63 %F=37		

Supplementary Table 2b. Pre-COVID era negative controls

Sample ID	Age	Sex	Used in Supp Fig 3 or as pooled negative
157	31-35	F	Pooled negative
158	41-45	F	Pooled negative
159	41-45	M	Pooled negative
160	31-35	F	Pooled negative
161	66-70	M	Pooled negative
162	20-25	F	Pooled negative
163	31-35	F	Pooled negative
164	26-30	F	Pooled negative
165	41-45	F	Pooled negative
166	31-35	M	Pooled negative
167	26-30	M	Pooled negative
168	41-45	F	Pooled negative
169	46-50	F	Pooled negative
170	36-40	F	Pooled negative
171	56-60	M	Pooled negative
172	36-40	M	Pooled negative
173	51-55	F	Pooled negative
174	15-19	M	Pooled negative
175	20-25	M	Pooled negative
176	46-50	M	Pooled negative
177	36-40	F	Pooled negative
178	36-40	F	Pooled negative
179	46-50	F	Pooled negative
180	41-45	F	Pooled negative
181	46-50	M	Pooled negative
182	51-55	F	Pooled negative
183	31-35	M	Pooled negative
184	31-35	F	Pooled negative
185	56-60	F	Pooled negative
186	51-55	F	Pooled negative
187	26-30	F	Pooled negative
188	36-40	M	Pooled negative
189	41-45	M	Pooled negative
190	31-35	F	Pooled negative
191	26-30	F	Pooled negative
192	36-40	F	Pooled negative
193	56-60	M	Pooled negative
194	41-45	M	Pooled negative
195	41-45	F	Pooled negative
196	36-40	F	Pooled negative
197	31-35	M	Pooled negative
198	36-40	M	Pooled negative
199	46-50	F	Pooled negative
200	41-45	F	Pooled negative
201	15-19	F	Pooled negative
202	26-30	F	Pooled negative
203	21-25	M	Pooled negative
204	36-40	F	Pooled negative

205	36-40	M	Pooled negative
206	31-35	F	Pooled negative
207	26-30	F	Pooled negative
208	31-35	M	Supp Fig 3 + pooled negative
209	32-35	M	Supp Fig 3 + pooled negative
210	41-45	M	Supp Fig 3 + pooled negative
211	51-55	F	Supp Fig 3 + pooled negative
212	56-60	M	Supp Fig 3 + pooled negative
213	56-60	F	Supp Fig 3 + pooled negative
214	46-50	F	Supp Fig 3 + pooled negative
215	41-45	M	Supp Fig 3 + pooled negative
216	41-45	M	Supp Fig 3 + pooled negative
217	36-40	F	Supp Fig 3 + pooled negative
218	46-50	M	Supp Fig 3 + pooled negative
219	41-45	F	Supp Fig 3 + pooled negative
220	51-55	M	Supp Fig 3 + pooled negative
221	41-45	F	Supp Fig 3 + pooled negative
222	26-30	M	Supp Fig 3 + pooled negative
223	41-45	F	Supp Fig 3 + pooled negative
224	26-30	M	Supp Fig 3 + pooled negative
225	31-35	M	Supp Fig 3 + pooled negative
226	36-40	M	Supp Fig 3 + pooled negative
227	41-45	F	Supp Fig 3 + pooled negative
228	36-40	F	Supp Fig 3 + pooled negative
229	15-19	M	Supp Fig 3 + pooled negative
230	20-25	F	Supp Fig 3 + pooled negative
231	46-50	F	Supp Fig 3 + pooled negative
232	56-60	F	Supp Fig 3 + pooled negative
233	61-65	M	Supp Fig 3 + pooled negative
234	36-40	F	Supp Fig 3 + pooled negative
Summary	Median age=39	%M=42 %F=58	

Supplementary Table 2c. COVID-19 patient data

Participant ID	Age	Sex	Days post symptom onset	Acute vs convalescent	Used in Fig 1, Supp Fig 3 or both
235	71-75	M	46	Convalescent	Supp Fig3
236	31-35	M	78	Convalescent	Supp Fig3
237	56-60	M	47	Convalescent	Supp Fig3
238	71-75	F	42	Convalescent	Supp Fig3
239	26-30	M	50	Convalescent	Supp Fig3
240	51-55	M	48	Convalescent	Supp Fig3
241	46-50	M	60	Convalescent	Supp Fig3
242	41-45	M	44	Convalescent	Supp Fig3
243	56-60	F	45	Convalescent	Supp Fig3
244	56-60	F	39	Convalescent	Supp Fig3
245	51-55	M	65	Convalescent	Supp Fig3
246	41-45	F	53	Convalescent	Supp Fig3
247	61-65	F	51	Convalescent	Supp Fig3
248	56-60	F	47	Convalescent	Supp Fig3
249	26-30	M	42	Convalescent	Supp Fig3
250	41-45	M	49	Convalescent	Supp Fig3
251	56-60	M	39	Convalescent	Supp Fig3
252	56-60	F	59	Convalescent	Supp Fig3
253	76-80	M	64	Convalescent	Supp Fig3
254	51-55	M	58	Convalescent	Supp Fig3
255	71-75	M	57	Convalescent	Supp Fig3
256	56-60	F	58	Convalescent	Supp Fig3
257	61-65	M	40	Convalescent	Supp Fig3
258	51-55	M	64	Convalescent	Supp Fig3
259	26-30	F	91	Convalescent	Supp Fig3
260	51-55	M	49	Convalescent	Supp Fig3
261	66-70	F	65	Convalescent	Supp Fig3
262	51-55	F	52	Convalescent	Supp Fig3
263	51-55	M	82	Convalescent	Both
264	51-55	M	75	Convalescent	Supp Fig3
265	26-30	F	56	Convalescent	Supp Fig3
266	61-65	M	31	Convalescent	Supp Fig3
267	76-80	F	47	Convalescent	Supp Fig3
268	66-70	F	40	Convalescent	Supp Fig3
269	46-50	M	50	Convalescent	Supp Fig3
270	81-85	F	67	Convalescent	Supp Fig3
271	61-65	M	62	Convalescent	Supp Fig3
272	71-75	M	80	Convalescent	Supp Fig3
273	56-60	M	104	Convalescent	Supp Fig3
274	71-75	M	40	Convalescent	Supp Fig3
275	81-85	M	17	Acute	Supp Fig3
276	41-45	M	44	Convalescent	Supp Fig3
277	81-85	M	13	Acute	Supp Fig3
278	36-40	F	51	Convalescent	Supp Fig3
279	61-70	F	53	Convalescent	Supp Fig3
280	36-40	M	45	Convalescent	Both
281	51-55	M	52	Convalescent	Both
282	46-50	M	9	Acute	Both
283	61-65	M	10	Acute	Both
284	56-60	M	69	Convalescent	Both

285	41-45	M	24	Convalescent	Both
286	81-85	F	11	Acute	Both
287	81-85	F	14	Acute	Both
288	81-85	M	5	Acute	Both
289	86-49	M	12	Acute	Supp Fig 3
290	91-95	F	10	Acute	Supp Fig 3
291	76-80	M	7	Acute	Supp Fig 3
292	76-80	M	10	Acute	Supp Fig3
293	46-50	M	13	Acute	Supp Fig3
294	56-60	M	8	Acute	Supp Fig3
295	56-60	M	11	Acute	Supp Fig3
296	56-60	F	11	Acute	Supp Fig3
297	96-100	F	3	Acute	Supp Fig3
298	96-100	F	6	Acute	Supp Fig3
299	61-65	M	15	Acute	Supp Fig3
280	36-40	M	19	Acute	Supp Fig3
281	61-65	F	3	Acute	Supp Fig3
282	81-85	F	12	Acute	Supp Fig3
283	61-65	F	9	Acute	Supp Fig3
284	66-70	M	36	Convalescent	Supp Fig3
285	31-35	F	40	Convalescent	Supp Fig3
286	31-25	F	75	Convalescent	Both
287	41-35	M	86	Convalescent	Both
288	71-75	F	96	Convalescent	Both
289				Acute	Fig 1
290				Acute	Fig 1
291				Acute	Fig 1
292				Acute	Fig 1
Summary	Median age =59	%M=61 %F=39	Average number of days post-symptom onset=42	%Acute=32 %Convalescent=68	

Supplementary Table 3a. Bivariate and multivariable analysis examining potential independent associations between log-transformed saliva anti-Spike IgA.

	Bivariate analysis	Multivariable analysis
Predictor	Beta coefficient (95% CI)	Beta coefficient (95% CI)
Age in years	0.02 (0.01 to 0.04)	0.02 (0.002 to 0.04)
Male sex	-0.4 (-1.1 to 0.3)	-0.4 (-1.1 to 0.3)
Time from vaccination to sample collection in days	0.01 (-0.03 to 0.05)	0.01 (-0.03 to 0.05)
Prior SARS-CoV-2 infection	1.0 (0.4 to 1.5)	0.9 (0.3 to 1.4)

Supplementary Table 3b. Bivariate and multivariable analysis examining potential independent associations between saliva anti-Spike IgG.

	Bivariate analysis	Multivariable analysis
Predictor	Beta coefficient (95% CI)	Beta coefficient (95% CI)
Age in years	0.6 (-0.1 to 1.2)	0.4 (-0.2 to 1.1)
Male sex	-38.7 (-65.2 to -12.2)	-39.5 (-65.7 to -13.3)
Time from vaccination to sample collection	-0.9 (-4.7 to 2.8)	-0.4 (-1.9 to 1.1)
Prior SARS-CoV-2 infection	21.3 (-0.3 to 42)	19.7 (-1.5 to 41)

Supplementary Table 3c. Bivariate and multivariable analysis examining potential independent associations between log-transformed serum anti-RBD IgA.

	Bivariate analysis	Multivariable analysis
Predictor	Beta coefficient (95% CI)	Beta coefficient (95% CI)
Age in years	0.005 (-0.006 to 0.02)	0.0008 (-0.01 to 0.01)
Male sex	0.2 (-0.2 to 0.7)	0.2 (-0.3 to 0.6)
Time from vaccination to sample collection	-0.04 (-0.06 to -0.01)	-0.04 (-0.06 to -0.01)
Prior SARS-CoV-2 infection	0.5 (0.1 to 0.9)	0.5 (0.2 to 0.9)

Abbreviations: CI = confidence interval

Supplementary Table 4. MSB-1 (longitudinal mRNA 2 doses cohort)

Participant ID	Age	Sex	Vaccination Type
293	20-25	F	BNT162b2
294	26-30	F	BNT162b2
295	26-30	M	BNT162b2
296	20-25	F	BNT162b2
297	20-25	M	BNT162b2
298	20-25	M	BNT162b2
299	20-25	M	BNT162b2
300	41-45	F	BNT162b2
301	20-25	M	BNT162b2
302	20-25	F	BNT162b2
303	31-35	F	BNT162b2
304	36-40	F	BNT162b2
305	56-50	M	BNT162b2
306	56-60	M	BNT162b2
307	20-25	F	BNT162b2
308	36-40	M	BNT162b2
309	20-25	F	BNT162b2
310	20-25	F	BNT162b2
311	31-35	M	BNT162b2
312	26-30	M	BNT162b2
313	26-30	F	BNT162b2
314	26-30	F	BNT162b2
315	26-30	F	BNT162b2
316	20-25	F	BNT162b2
317	26-30	M	BNT162b2
318	46-50	M	BNT162b2
319	41-45	F	BNT162b2
320	41-45	F	BNT162b2
321	26-30	F	BNT162b2
322	26-30	M	BNT162b2
Summary	Median age=27	%M=42 %F=56	

Supplementary Table 5. MSB-2 cohort (ChAdOx1-S dose 1, mRNA dose 2)

Participant ID	Age	Sex	Second vaccination type
323	56-60	F	BNT162b2
324	51-55	F	mRNA1273
325	36-40	F	mRNA1273
326	51-55	F	BNT162b2
327	46-50	F	BNT162b2
328	56-60	F	mRNA1273
329	56-60	F	mRNA1273
330	41-45	F	BNT162b2
331	46-50	F	BNT162b2
332	41-50	F	BNT162b2
333	71-75	M	BNT162b2
334	46-50	M	mRNA1273
335	46-50	M	BNT162b2
336	56-60	M	BNT162b2
337	41-45	F	BNT162b2
338	46-50	M	BNT162b2
339	41-45	M	BNT162b2
340	41-45	Other	BNT162b2
341	41-45	F	BNT162b2
342	56-60	F	BNT162b2
343	71-75	F	BNT162b2
344	61-65	M	BNT162b2
345	56-60	F	BNT162b2
346	61-65	F	BNT162b2
347	36-40	M	mRNA1273
348	51-55	M	mRNA1273
349	36-40	M	mRNA1273
350	56-60	F	BNT162b2
351	41-45	F	mRNA1273
352	66-70	F	mRNA1273
353	51-55	F	mRNA1273
354	61-65	M	BNT162b2
355	61-65	F	BNT162b2
356	61-65	M	BNT162b2
357	56-60	M	BNT162b2
358	46-50	F	mRNA1273
359	46-50	M	BNT162b2
360	41-45	F	BNT162b2
361	41-45	F	BNT162b2
362	56-60	F	BNT162b2
363	66-70	M	mRNA1273
Summary	Median Age= 52.5	%M=61 %F= 39	%BNT162b2=68 %mRNA1273=32